Recent advances in mRNA-based vaccine for cancer therapy; bench to bedside.
Cell Biochem Funct
; 42(2): e3954, 2024 Mar.
Article
en En
| MEDLINE
| ID: mdl-38403905
ABSTRACT
The messenger RNA (mRNA) vaccines have progressed from a theoretical concept to a clinical reality over the last few decades. Compared to conventional vaccination methods, these vaccines have a number of benefits, such as substantial potency, rapid growth, inexpensive production, and safe administration. Nevertheless, their usefulness was restricted up to now due to worries about the erratic and ineffective circulation of mRNA in vivo. Thankfully, these worries have largely been allayed by recent technological developments, which have led to the creation of multiple mRNA vaccination platforms for cancer and viral infections. The mRNA vaccines have been demonstrated as a powerful alternative to traditional conventional vaccines because of their high potency, safety and efficacy, capacity for rapid clinical development, and potential for rapid, low-cost manufacturing. The paper will examine the present status of mRNA vaccine technology and suggest future paths for the advancement and application of this exciting vaccine platform as a common therapeutic choice.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vacunas
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Cell Biochem Funct
Año:
2024
Tipo del documento:
Article
País de afiliación:
Irak
Pais de publicación:
Reino Unido